医学
核医学
肾细胞癌
标准摄取值
淋巴
PET-CT
淋巴结
放射科
正电子发射断层摄影术
病理
作者
Shuhui Huang,Haoyang Liu,Hongyuan Dai,Mengfang Qi,Minggang Su,Hao Zeng,Rui Huang
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2024-07-10
标识
DOI:10.1097/rlu.0000000000005367
摘要
Purpose Fumarate hydratase-deficient renal cell cancer (FHRCC) is a rare and aggressive form of renal cell carcinoma. The diagnostic value of 68 Ga-FAPI PET/CT for FHRCC remains unexplored. Therefore, we compared the potential value of 68 Ga-FAPI-04 and 18 F-FDG PET/CT in FHRCC. Patients and Methods Patients with FHRCC underwent 68 Ga-FAPI-04 and 18 F-FDG PET/CT from May 2022 to December 2023. The SUV max and tumor-to-liver ratio (TLR) of both tracers were compared using the Wilcoxon signed rank test. Results Eleven patients with 83 lesions were enrolled. The rate of 18 F-FDG PET/CT in detecting lesions was higher than that of 68 Ga-FAPI-04 PET/CT: primary tumors: 75.0% (6/8) versus 50.0% (4/8); lymph nodes: 94.9% (37/39) versus 89.7% (35/39); and bone lesions: 100.0% (21/21) versus 90.5% (19/21). The median SUV max of primary and metastatic lesions on 18 F-FDG PET/CT was comparable to 68 Ga-FAPI-04 PET/CT in semiquantitative analysis (primary lesions: 13.86 vs 16.35, P = 1.000; lymph nodes: 10.04 vs 9.33, P = 0.517; bone lesions: 13.49 vs 9.84, P = 0.107; visceral lesions: 8.54 vs 4.20, P = 0.056). However, the median TLRs of primary and metastatic lesions on 68 Ga-FAPI-04 PET/CT were higher than that of 18 F-FDG PET/CT (primary lesions: 30.44 vs 5.41, P = 0.010; lymph nodes: 17.71 vs 3.95, P = 0.000; bone lesions: 15.94 vs 5.21, P = 0.000; visceral lesions: 9.26 vs 3.44, P = 0.003). Conclusions 18 F-FDG PET/CT detected more primary and metastatic FHRCC lesions than 68 Ga-FAPI-04 PET/CT. However, the higher TLR in FHRCC on 68 Ga-FAPI-04 PET/CT may indicate therapeutic potential in targeting fibroblast activation protein in FHRCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI